Navigation Links
DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
Date:2/9/2011

CUPERTINO, Calif., Feb. 9, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb shoulder clinical trial conducted by Nycomed of POSIDUR™ (also known as SABER™-bupivacaine or Optesia™ in the E.U.), a proprietary product under development for the treatment of post-surgical pain, and the amendment of the Company's collaboration agreement with Nycomed.

(Logo:  http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

This shoulder trial is part of Nycomed's clinical development program for Europe for POSIDUR.  In this study, 107 patients were randomly assigned to one of three treatment groups prior to undergoing elective arthroscopic shoulder surgery: POSIDUR at a dose of 5 mL, an active comparator (commercially available bupivacaine HCI solution) or SABER-Placebo (SABER vehicle without drug).  All patients were given a background pain treatment consisting of a daily dose of two or four grams (depending on the patient's weight) of paracetamol (acetaminophen).  In addition, each patient was provided supplemental opioid rescue medication, if needed.

The primary efficacy endpoints of this Phase IIb study were to demonstrate: (1) non-inferiority of POSIDUR to SABER-Placebo (with all groups taking the background and supplemental pain treatment as described above) in terms of pain intensity on movement area under the curve (AUC) during the period 1-72 hours post-surgery, and (2) superiority of POSIDUR against SABER-Placebo in the total use of opioid rescue analgesia 0-72 hours post-surgery.  Top-line results from this study demonstrate that the POSIDUR group experienced a statistically significant reduction in pain intensity versus SABER-Placebo. The results of the pre-specified primary analysis indicated a clear clin
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... --  Ventana Medical Systems, Inc.  (Ventana), a member of ... an agreement with Merck KGaA, Darmstadt, Germany ... the United States and ... division on the development and commercialization of a companion ... diagnostic assays. In alignment with Merck KGaA,s strategic approach ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... 2011 iAdvantage Software, Inc. , ... life science studies, today announced that BioTox Sciences ... San Diego, California, is deploying the eStudy™ ... preclinical/nonclinical studies . (Logo: http://photos.prnewswire.com/prnh/20110309/CL62195LOGO) ...
... Reportlinker.com announces that a new market research ... Cancer Vaccines - Pipeline Assessment and Market ... Cancer Vaccines - Pipeline Assessment ... SummaryGlobalData, the industry analysis specialist,s new report, "Cancer ...
Cached Medicine Technology:BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 2BioTox Sciences (BTS) Deploys eStudy™ Hosted Solution for Management of GLP & Non-GLP Preclinical Studies 3Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:7/11/2014)... July 11, 2014 Global enterprises today ... to outsource day-to-day management activities. Managed services offer these ... expenses. The economic slowdown resulted into rising operational costs ... expenses is considered to be the global market driver ... , The global managed services market is estimated to ...
(Date:7/11/2014)... As reported by the New York ... significant number of severe adverse events such as renal ... death from the highly-promoted and costly immune-system drug, Acthar, ... report , a regulatory filing revealed that the total ... almost 14% of prescriptions, up from 9.1% in 2011. ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... Steven Reinberg HealthDay Reporter ... to protect children from the worldwide scourge of dengue fever ... While the vaccine only prevented dengue fever in 56 percent ... three shots, it protected more than 88 percent of them ... lead to hospitalization, and sometimes death. "This vaccine has ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
Breaking Medicine News(10 mins):Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3
... who drink more than 15 drinks of alcohol a ... like anxiety disorder and depression. ,Researchers of University ... the study said that there is a significant link ... research study has been the largest longitudinal study in ...
... Health, US, have found out //that almost 50% of the ... early as the teenage and may remain undetected for a ... in spite of efficient treatments available, patients stay untreated for ... disorders once diagnosed, difficult to treat as they become more ...
... Gold nanoparticles may be used to detect cancer, says a ... ,The father and son research team had been able ... cells, a process that will make the tracing of cancer ... called epidermal growth factor receptor (EFGR) over their surface. This ...
... screening of the mouth by trained health workers can help ... the oral cancer mortality rate. ,A research done by ... possible to visually screen people for oral cancer in order ... of oral cancer patients. ,Oral cancer is the growth ...
... women take is affected by factors like stress, mood, //anxiety ... the American Dietetic Association. ,Diet in pregnancy is very ... contain the food elements like folic acid and other vitamins ... women who are more often exhausted or stressed tend to ...
... cancer may have higher risks of having cognitive// impairment ... of Southern California had found that patients who survived ... as much risk as their healthy counterparts of having ... of cancer and their twins with the help of ...
Cached Medicine News:
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
... for applications such as vasectomy that ... ,The autoclavable handpiece with six-foot cord ... cautery electrodes, allowing the physician to ... wide variety of procedures., ,The 2201 ...
No Scalpel Vasectomy Hemostat 5 1/2" (14cm), smooth sharp point, curved, gold finger rings...
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company....
Medicine Products: